Patents by Inventor Cécile Voisset

Cécile Voisset has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220273637
    Abstract: The invention relates to novel compounds which are inhibitors of the ribosome protein chaperone activity (“protein folding activity of the ribosome” or “PFAR”). More particularly, the invention relates to their use as PFAR-inhibitors, to compositions comprising them and to methods for treating proteinopathies.
    Type: Application
    Filed: July 9, 2020
    Publication date: September 1, 2022
    Inventors: MARTINE SIMONELIG, FRÉDÉRIC BIHEL, CÉCILE VOISSET, CAPUCINE TROLLET
  • Patent number: 11406631
    Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 9, 2022
    Assignees: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko
  • Publication number: 20210161887
    Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
    Type: Application
    Filed: April 3, 2019
    Publication date: June 3, 2021
    Applicants: Universite de Bretagne Occidentale, Centre Hospitalier Regional Universitaire de Brest, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris, Univ Paris XIII Paris-Nord Villetaneuse, Universite Paris-Saclay
    Inventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko
  • Patent number: 7632931
    Abstract: The invention concerns an endogenic nucleic fragment, such as an isolated retrovirus, integrated in the human DNA genome, the fragment being characterized in that it comprises, or consists of, at least part of the gag gene of an endogenetic retrovirus associated with an autoimmune disease or pregnancy failure or pregnancy pathologies, said part at least coding, directly and indirectly, for an expression product, or the complement of the fragment.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: December 15, 2009
    Assignee: Biomerieux
    Inventors: Glaucia Paranhos-Baccala, Francois Mallet, Cecile Voisset
  • Publication number: 20040048298
    Abstract: The invention concerns an endogenic nucleic fragment, such as an isolated retrovirus, integrated in the human DNA genome, the fragment being characterized in that it comprises, or consists of, at least part of the gag gene of an endogenetic retrovirus associated with an autoimmune disease or pregnancy failure or pregnancy pathologies, said part at least coding, directly and indirectly, for an expression product, or the complement of the fragment.
    Type: Application
    Filed: August 4, 2003
    Publication date: March 11, 2004
    Applicant: BIO MERIEUX
    Inventors: Glaucia Paranhos-Baccala, Francois Mallet, Cecile Voisset